Quantcast

Latest Biodefense Stories

2014-09-23 08:29:51

PRINCETON, N.J., Sept. 23, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has appointed Rasappa Arumugham, PhD, as its Vice President of Biopharmaceutical Development. Dr. Arumugham has over 25 years of diverse experience in biopharmaceutical research and development (R&D) in the...

2014-09-19 08:25:40

PRINCETON, N.J., Sept. 19, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has been awarded a contract valued at up to $24.7 million inclusive of options by the US Department of Health and Human Service's National Institutes of Health (NIH) (specifically funded by the National Institute...

2014-09-15 23:07:02

BioFactura, Inc. is a collaborator on a grant awarded to the Geneva Foundation. Eboladrug development funding will be provided under a Partnerships for Biodefense grant from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID). Frederick, MD (PRWEB) September 15, 2014 BioFactura, Inc. is a collaborator on a grant awarded to the Geneva Foundation. Ebola drug development funding will be provided under a Partnerships for Biodefense grant from...

2014-09-10 08:32:30

ANNAPOLIS, Md., Sept. 10, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a contract, valued at up to $28.1 million if all contract options are exercised, for the development of a next generation anthrax vaccine based on the...

2014-09-09 08:33:14

ANNAPOLIS, Md., Sept. 9, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that recent non-clinical animal data from its SparVax(®) anthrax vaccine program were presented at the 54(th) Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, DC. In a poster presentation entitled, "Enhanced Next Generation rPA Vaccine Induces Immunogenicity and Efficacy at Least Equivalent to AVA in the New Zealand White (NZW) Rabbit Model for Anthrax," Dr....

2014-09-09 08:30:50

New patent includes composition of matter claims PRINCETON, N.J., Sept. 9, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the US Patent and Trademark Office (US PTO) granted patent 8,808,710 entitled "Method of Preparing an Immunologically-Active Adjuvant-Bound Dried Vaccine...

2014-09-08 12:21:08

ANNAPOLIS, Md., Sept. 8, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that Eric I. Richman, President and Chief Executive Officer will present at the following investment conferences. Event: Rodman & Renshaw 16(th) Annual Global Investment Conference Date: Tuesday, September 9, 2014 Place: New York Palace Hotel, New York, NY Time: 11:40 a.m. EDT; Kennedy...

2014-09-08 12:20:37

Companies Combine Expertise and Resources to Advance Medical Countermeasures Development and Manufacturing ANNAPOLIS, Md. and ALACHUA, Fla., Sept. 8, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) and Nanotherapeutics, Inc., a privately-held biopharmaceutical company, announced today that they have formed a Strategic Alliance to advance the development of certain medical countermeasures for the U.S. biodefense market. Under the Alliance Agreement, each company will contribute its...

2014-09-08 08:29:28

Presentation to be Webcast Live, 1:15 PM EDT, September 9th PRINCETON, N.J., Sept. 8, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will give a corporate presentation at the 16(th) Annual Rodman & Renshaw Global...

2014-09-02 08:29:01

All vaccinated animals exposed to a lethal aerosol of ricin toxin survive PRINCETON, N.J., Sept. 2, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today promising preliminary results from a preclinical study with its ricin...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related